2. Dick FD, De Palma G, Ahmadi A, Scott NW, Prescott GJ, Felice A. Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study. Occup Environ Med. 2017;64:666–672.
3. Braak H, Del Tredici K, Rüb U, de Vos RA, Steur ENJ, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211.
4. Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord. 2010;25:2493–2500.
5. Khedr EM, El Fetoh NA, Khalifa H, Ahmed MA, El Beh KMA. Prevalence of non motor features in a cohort of Parkinson’s disease patients. Clin Neurol Neurosurg. 2013;115:673–677.
6. Nègre-Pagès L, Grandjean H, Lapeyre-Mestre M, Montastruc JL, Fourrier A, Lépine JP, et al. Anxious and depressive symptoms in Parkinson’s disease: the French cross-sectional DoPAMiP study. Mov Disord. 2010;25:157–166.
7. Degardin A, Houdayer E, Bourriez JL, Destée A, Defebvre L, Derambure P, et al. Deficient “sensory” beta synchronization in Parkinson’s disease. Clin Neurophysiol. 2009;120:636–642.
8. Schulte EC, Winkelmann J. When Parkinson’s disease patients go to sleep: specific sleep disturbances related to Parkinson’s disease. J Neurol. 2011;258:328–335.
9. Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O’Brien JT, Brooks DJ, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013;80:276–281.
10. Oh Y-S, Kim JS, Hwang EJ, Lyoo CH. Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson’s disease. Parkinsonism Relat Disord. 2018;56:47–51.
11. Hawkes CH, Shephard BC, Daniel SE. Is Parkinson’s disease a primary olfactory disorder? QJM. 1999;92:473–480.
12. Munhoz PR, Moro LA, Silveira-Moriyama L, Teive HA. Non-motor signs in Parkinson’s disease: A review. Arq Neuropsiquiatr. 2015;73:454–462.
13. Vennemann MM, Hummel T, Berger K. The association between smoking and smell and taste impairment in the general population. J Neurosci. 2008;255:1121–1126.
15. Vickers AJ. How to randomize. J Soc Integr Oncol. 2006;4:194–198.
17. The R Foundation [Internet]. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria: 2018. Available from:
https://www.R-project.org/.
18. Ikemoto S. Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory. Neurosci Biobehav Rev. 2010;35:129–150.
19. Iannilli E, Stephan L, Hummel T, Reichmann H, Haehner A. Olfactory impairment in Parkinson’s disease is a consequence of central nervous system decline. J Neurol. 2017;264:1236–1246.
20. Miwa T, Furukawa M, Tsukatani T, Costanzo RM, DiNardo LJ, Reiter ER. Impact of olfactory impairment on quality of life and disability. Arch Otolaryngol Head Neck Surg. 2001;127:497–503.
21. Soudry Y, Lemogne C, Malinvaud D, Consoli SM, Bonfils P. Olfactory system and emotion: Common substrates. Eur Ann Otorhinolaryngol Head Neck Dis. 2011;128:18–23.
22. Rochet M, El-Hage W, Richa S, Kazour F, Atanasova B. Depression, Olfaction, and Quality of Life: A Mutual Relationship. Brain Sci. 2018;8:80.
25. Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol. 2003;53:26–38.
26. Crotty GF, Ascherio A, Schwarzschild MA. Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol. 2017;298:210–224.
27. Asanuma M, Miyazaki I, Ogawa N. Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox Res. 2003;5:165–176.
28. Zhang L, Zhang L, Li L, Holscher C. Semaglutide is neuroprotective and reduces a-synuclein levels in the chronic MPTP mouse model of Parkinson’s disease. J Parkinsons Dis. 2019;9:157–171.
29. Gratuze M, Josset N, Petry FR, Pflieger M, Jong LE, Truchetti G, et al. The toxin MPTP generates similar cognitive and locomotor deficits hTau and Tau knock-out mice. Brain Res. 2019;1711:106–114.
30. Love S, Jenner P. Oxidative stress in neurological disease. Brain Pathol. 2006;9:55–56.
33. Hussain A, Pooryasin A, Zhang M, Loschek LF, Fortezza ML, Friedrich AB, et al. Inhibition of Oxidative Stress in Cholinergic Projection Neurons Fully Rescues Aging-Associated Olfactory Circuit Degeneration in Drosophila. Elife. 2018;10:32018.
34. Stowe R, Ives N, Clarke CE, Deane K, van Hilten S, Wheatley K, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson’s disease patients with motor complications. Cochrane Database Syst Rev. 2010;7:CD007166.
35. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25:2649–2653.
37. Singh M, Girishan KVS, Bajaj J, Garg K. Deep brain stimulation for movement disorders: Surgical nuances. Neurol India. 2018;66:122–130.
38. Poewe W. Treatments for Parkinson disease—past achievements and current clinical needs. Neurology. 2009;72:65–73.
39. Yu-Wai-Man P. Genetic manipulation for inherited neurodegenerative diseases: myth or reality? Br J Ophthalmol. 2016;100:1322–1331.
40. Lee SH, Lim S. Clinical effectiveness of acupuncture on Parkinson disease: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e5836.
41. Xia Y, Wang HD, Ding Y, Kang B, Liu WG. Parkinson’s disease combined with depression treated with electroacupuncture and medication and its effect on serum BDNF. Zhongguo Zhen Jiu. 2012;32:1071–1074. [in Chiense].
42. Arankalle DV, Nair PM. Effect of electroacupuncture on function and quality of life in Parkinson’s disease: A case report. Acupunct Med. 2013;31:235–238.
44. Yu Y, Ju W, Li Z, Wang D, Wang Y, Xie A. Acupuncture inhibits oxidative stress and rotational behavior in 6-hydroxydopamine lesioned rat. Brain Res. 2010;1336:58–65.
45. Kang JM, Park HJ, Choi YG, Choe IH, Park JH, Kim YS, et al. Acupuncture inhibits microglial activation and inflammatory events in the MPTP induced mouse model. Brain Res. 2007;1131:211–219.
46. Huo LR, Liang XB, Li B, Liang JT, He Y, Wang XM. The cortical and striatal gene expression profile of 100 Hz electroacupuncture treatment in 6-hydroxydopamine-induced Parkinson’s disease model. Evid Based Complement Alternat Med. 2012;2012:908439.
47. Wayne PM, Manor B, Novak V, Costa MD, Hausdorff JM, Goldberger AL, et al. A Systems Biology Approach to Studying Tai Chi, Physiological Complexity and Healthy Aging: Design and Rationale of a Pragmatic Randomized Controlled Trial. Contemp Clin Trials. 2012;34:21–34.
48. Song R, Grabowska W, Park M, Osypiuk K, Vergara-Diaz G, Bonato GP, et al. The impact of Tai Chi and Qigong mind-body exercises on motor and non-motor function and quality of life in Parkinson’s disease: A systematic review and meta-analysis. Parkinsonism Relat Disord. 2017;41:3–13.
49. Liu XL, Chen S, Wang Y. Effects of health qigong exercises on relieving symptoms of Parkinson’s disease. Evid Based Complement Alternat Med. 2016;2016:5935782.